Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue Disease  by Zellweger, Raphaël M. et al.
Cell Host & Microbe
ArticleEnhanced Infection of Liver Sinusoidal
Endothelial Cells in a Mouse Model
of Antibody-Induced Severe Dengue Disease
Raphae¨l M. Zellweger,1,2 Tyler R. Prestwood,1,2 and Sujan Shresta1,*
1Division of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
2These authors contributed equally to this work
*Correspondence: sujan@liai.org
DOI 10.1016/j.chom.2010.01.004SUMMARY
Dengue virus (DENV) causes disease ranging from
dengue fever (DF), a self-limited febrile illness, to
the potentially lethal dengue hemorrhagic fever
and dengue shock syndrome (DHF/DSS). DHF/DSS
usually occurs in patients who have acquired DENV-
reactive antibodies prior to infection, either from
a previous infection with a heterologous DENV sero-
type or from an immune mother. Hence, it has been
hypothesized that subneutralizing levels of anti-
bodies exacerbate disease, a phenomenon termed
antibody-dependent enhancement (ADE). However,
given the lack of suitable animal models for DENV
infection, the mechanism of ADE and its contribution
to pathology remain elusive. Here we demonstrate in
mice that DENV-specific antibodies can sufficiently
increase severity of disease so that a mostly nonle-
thal illness becomes a fatal disease resembling
human DHF/DSS. Antibodies promote massive infec-
tion of liver sinusoidal endothelial cells (LSECs),
resulting in increased systemic levels of virus. Thus,
a subprotective humoral response may, under some
circumstances, have pathological consequences.
INTRODUCTION
The four serotypes of dengue virus (DENV1–4), a flavivirus trans-
mitted to humans by Aedes mosquitoes, induce a spectrum of
disease ranging from dengue fever (DF), an acute, self-limited
febrile illness, to the life-threatening dengue hemorrhagic fever
and dengue shock syndrome (DHF/DSS), characterized by
plasma leakage, low platelet counts, liver damage, elevated
cytokine levels (‘‘cytokine storm’’), and, in the most severe
cases, death due to shock (Halstead, 2007). Two and a half
billion people in tropical and subtropical regions are at risk of
infection, and it is estimated that 50–100 million cases occur
annually, of which 500,000 are severe and 15,000 are fatal
(Rico-Hesse, 2007). Epidemiological studies suggest that DHF/
DSS occurs predominantly during either secondary infection
with a heterologous serotype (Halstead et al., 1967) or primary
infection in 6- to 9-month-old infants of DENV-immune mothers128 Cell Host & Microbe 7, 128–139, February 18, 2010 ª2010 Elsev(Halstead, 1982). Therefore, it appears that nearly all severe
dengue cases occur in patients who have acquired DENV-reac-
tive antibody prior to infection, either actively from a previous
infection or passively from an immune mother. Accordingly, it
has been hypothesized that subneutralizing levels of DENV-
specific antibodies exacerbate disease by increasing infection
of cells bearing Fc-g receptors (FcgRs), a phenomenon termed
antibody-dependent enhancement of infection (ADE) (Halstead,
2003). However, little is known about the mechanism of ADE
in vivo and its contribution to pathology, as increased disease
severity due to antibodies has never been demonstrated in vivo.
Here we demonstrate that administering anti-DENV antibodies
to DENV-infected mice can sufficiently exacerbate disease so
that a mostly nonlethal illness turns into a fatal disease resem-
bling human DHF/DSS. Massively enhanced infection of liver
sinusoidal endothelial cells (LSECs) occurred in mice treated
with DENV-specific antibodies. Following enhanced infection
of LSECs, mice exhibited increased levels of virus in other
tissues, cytokine storm, low platelet counts, increased vascular
permeability, intestinal hemorrhage, and ultimately death.RESULTS
Subprotective Levels of Antibody Enhance Severity
of Dengue Disease in Mice
Epidemiological observations and in vitro studies have provided
the majority of the evidence for the occurrence of ADE. In vitro,
subneutralizing concentrations of DENV-specific antibodies
enhanced viral replication in mononuclear phagocytes (Halstead
et al., 1977). In vivo, passive transfer of immune serum (Halstead,
1979) or antibodies (Goncalvez et al., 2007) into DENV-infected
rhesus monkeys resulted in increased viremia, although signs
of disease were not apparent. However, to date, it has not
been determined whether antibodies alone can exacerbate
DENV-induced disease.
To investigate the effect of DENV-specific antibodies in vivo,
type I and II interferon (IFN) receptor-deficient 129/Sv mice
(AG129) were administered 200 ml of DENV1-, 2-, 3-, or
4-immune serum (obtained from AG129 mice infected with
1.5 3 106 FACS infectious units [FIUs] of DENV) or naive serum
1 day before and 1 day after i.v. infection with 5 3 108 genomic
equivalents (GE) (approximately 104 PFU) of the DENV2 strain
S221, a triple-plaque-purified clone isolated from a mouse-
passaged DENV2 strain (Shresta et al., 2006). Mice administeredier Inc.
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Figure 1. Heterologous ImmuneSerumDecreasesMeanSurvival Time of DENV-InfectedMice, Homologous SerumProtects 50%of theMice
from Disease
(A) Survival of DENV-infected AG129 mice (53 108 GE S221 i.v.) in the presence of heterologous DENV1-, 3-, or 4-immune serum, homologous DENV2-immune
serum (black triangles), or naive serum (white triangles); 200 ml of serum was administered i.p. on days 1 and 1. P values from Gehan-Breslow-Wilcoxon test,
n = 4–6 mice per group.
(B) DENV2-reactive IgG in the sera used in (A) was measured by ELISA on plates coated with sucrose gradient-purified S221.
(C) Biological activity of the sera used in (A) was assessed by measuring their ability to reduce infection of C6/36 cells by DENV2. For clarity, a dotted line has been
added at 50% infection.
For comparison purposes, the naive serum curve is depicted in all panels.
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ADE of LSEC Infection and Dengue Disease in MiceDENV1-, 3-, or 4-immune serum died from severe disease 4–5
days after infection, without manifesting neurologic abnormali-
ties, whereas mice treated with naive serum were sacrificed
when they developed signs of paralysis 7–12 days after infection
(Figure 1A). Half of the mice administered DENV2-immune serum
were protected from disease and survived much longer than
control mice (33% survived over 30 days), whereas the other
half exhibited the early, severe disease phenotype. All immune
sera contained DENV2-reactive antibodies (Figure 1B), although
the DENV2-immune serum contained about ten times more than
the others. The ability of the sera to reduce infection of C6/36
mosquito cells by the DENV2 strain S221 was measured (Fig-
ure 1C), and the DENV2-immune serum neutralized virus 15–20
times better than the DENV1-, 3-, or 4-immune sera. Naive
serum at low dilutions was able to prevent infection of C6/36
cells; however, this effect is likely independent of antibodies,
as similar observations were made with serum obtained from
mMt mice, which lack antibodies (data not shown). Notably,
DENV2-immune serum obtained from AG129 mice infected
with a higher dose of virus (4.0 3 107 FIU, instead of 1.5 3 106
FIU as in Figure 1), completely protected against disease in
recipient mice infected with 5 3 108 GE of S221 i.v. (data notCell Hostshown). These results demonstrate that while heterologous
immune serum exacerbates disease in DENV-infected mice,
homologous serum can protect from disease.
To confirm that antibodies were responsible for the decreased
survival time observed in mice treated with immune serum, the
capacity of purified monoclonal antibodies (mAbs) to enhance
disease was tested. AG129 mice were administered 15 mg of
mouse monoclonal antibody 2H2 (IgG2a anti-membrane protein
[prM/M], DENV1-4 reactive), 4G2 (IgG2a anti-envelope pro-
tein [E], pan-flavivirus-reactive), or 3H5 (IgG1 anti-E, DENV2-
specific) and infected with S221 (anti-DENV-treated mice). Iso-
type-treated mice were administered an isotype-matched
antibody of irrelevant specificity. Anti-DENV-treated mice
exhibited severe disease and died 4–5 days after infection,
whereas isotype-treated mice survived longer and were sacri-
ficed when they developed neurological symptoms around
8–13 days after infection (Figure 2A), demonstrating that ADE
is not restricted to one IgG subclass or DENV epitope.
To determine the relationship between disease outcome and
the amount of antibody administered, doses ranging from
0.5 to 500 mg of the neutralizing mAb 4G2 were administered
to S221-infected mice. While mice treated with 2 and 15 mg& Microbe 7, 128–139, February 18, 2010 ª2010 Elsevier Inc. 129
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Figure 2. Subprotective Levels of Anti-DENV Monoclonal Antibodies Decrease Mean Survival Time of DENV-Infected Mice
(A) Survival of DENV-infected AG129 mice treated on days 1 and 1 with 15 mg of anti-DENV antibody (black squares, n = 7–12) or an isotype control (white
squares, n = 12–20). Various anti-DENV antibodies were used, see figure and text for details. As the same isotype control was used for both IgG2a antibodies,
the same isotype control curve is depicted in the left and middle panels.
(B) Mean survival time of DENV-infected AG129 mice treated with 0.5, 2, 15, 200, or 500 mg of IgG2a against DENV E (clone 4G2, black bars, n = 4–7), 500 mg of an
isotype control (white bar, n = 7) or PBS (gray bar, n = 11). For simplicity, statistically significant differences are indicated only between the PBS-treated group and
the anti-DENV-treated groups.
(C) Survival of AG129 mice infected intradermally (i.d.) with 53 108 GE S221 and treated with anti-DENV antibodies (black squares, n = 7) or isotype control (white
squares, n = 7). IgG2a (15 mg) against DENV prM/M was administered i.p. on days 1 and 1.
(D) Survival of AG129 mice infected with 5 3 107 or 5 3 106 GE S221 i.v. and treated with anti-DENV antibodies (black squares, n = 4) or isotype control (white
squares, n = 4). Antibody was administered as in (C).
(E) Survival of A129 mice infected on day 0 with 13 1011 GE S221 i.v. and treated on days1, 1, 2, and 3 with 50 mg of IgG2a against DENV prM/M (black squares,
n = 8) or an isotype control (white squares, n = 9).
P values from Gehan-Breslow-Wilcoxon test (A and C–E) or two-tailed unpaired t test with Welch’s correction, c.i. 95% (B), *p% 0.05, **p% 0.01, ***p% 0.001,
error bars represent SEM, n is the number of mice per group.
Cell Host & Microbe
ADE of LSEC Infection and Dengue Disease in Miceexhibited severe disease and decreased survival time, mice
administered 500 mg were protected from severe disease and
survived longer than control mice (Figure 2B). These results
show that, depending on the concentration, a neutralizing anti-
body can either increase or decrease disease severity.
Decreased survival following administration of DENV-reactive
mAbs was also observed in AG129 mice infected intradermally
(i.d.) with 5 3 108 GE S221 (Figure 2C), in AG129 mice infected
i.v. with 5 3 107 or 5 3 106 GE S221 (Figure 2D), and in 129/Sv
mice lacking only the type I IFN receptor (A129), although a higher
amount of antibody and a 200-fold greater dose of virus were
necessary to induce severe disease in these mice compared to
AG129 (Figure 2E). Therefore, ADE-induced severe dengue
disease occurs under various experimental conditions.
Further experiments were performed in AG129 mice infected
with 5 3 108 GE S221 i.v. on day 0 and treated on days 1
and 1 with 15 mg 2H2 (anti-DENV-treated mice) or an isotype
control unless stated otherwise. At this dose, it was possible to
assess how antibodies turn a mostly nonlethal disease in
isotype-treated mice into a lethal disease resembling DHF/DSS
in anti-DENV-treated mice.
Disease Induced by Subprotective Levels of Antibodies
in DENV-Infected Mice Resembles DHF/DSS
Elevated levels of various cytokines (IL-6, IL-10, IL-8, IFN-g)
(Chaturvedi et al., 2000), presence of TNF (Green et al., 1999),130 Cell Host & Microbe 7, 128–139, February 18, 2010 ª2010 Elsevincreased vascular permeability (Halstead, 2007), thrombocyto-
penia (Halstead, 2007), increased hematocrit (Kittigul et al.,
2007), and gastrointestinal bleeding (Chiu et al., 2005) are hall-
marks of DHF/DSS in humans. Anti-DENV-treated mice had
significantly higher levels of TNF, IL-6, and IL-10 compared to iso-
type-treated mice 90 hr after infection (Figure 3A). In addition,
IL-1b, IL-9, IL-12(p40), IL-17, KC, G-CSF, and RANTES were
elevated in anti-DENV-treated mice compared to isotype-treated
mice 72 and/or 90 hr after infection (see Figure S1 available
online). Neither IL-6 neutralization nor IL-10 receptor blockade
had any effect on the survival time of anti-DENV-treated mice,
but neutralization of TNF prevented early death (Figure 3B).
Shortly before succumbing, anti-DENV-treated mice exhibited
low platelet counts (Figure 3C); elevated hematocrit (Figure 3D);
increased vascular permeability in the liver, as measured by
extravasation of Evans blue (Figure 3E); and gastrointestinal
hemorrhage (Figure 3F), paralleling DHF/DSS symptoms.
Antibodies Mediate Increased Levels of Virus First
in the Liver and Later in Other Organs
In the liver of anti-DENV-treated mice, levels of viral RNA were
8-fold, 42-fold, and 10-fold higher than isotype-treated mice
48, 72, and 90 hr after infection, respectively (Figure 4A). In the
small intestine, levels of viral RNA were 3.3-fold higher at 72 hr
and 10-fold higher at 90 hr (Figure 4A). In the spleen and serum,
respectively, RNA levels were 4.2-fold and 2.8-fold higher atier Inc.
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Figure 3. Administration of Anti-DENV Antibodies Induces a DHF/DSS-like Disease in DENV-Infected Mice
AG129 mice were infected with 5 3 108 GE S221 and administered 15 mg IgG2a against DENV prM/M on days 1 and 1.
(A) IL-6, IL-10, and TNF levels in the serum of DENV-infected mice 48, 72, and 90 hr after infection (n = 3–9).
(B) Mean survival time of anti-DENV-treated mice in which IL-6, IL-10R, or TNF was neutralized or blocked (black bars, n = 4–6); control groups were treated with
the respective isotype controls of the IL-6, IL-10R, or TNF blocking antibodies (white bars, n = 4–6).
(C) Platelet counts 90 hr after infection (n = 6–7).
(D) Hematocrit 90 hr after infection (n = 6–7).
(E) Vascular permeability in the liver of naive mice and DENV-infected mice in the presence of isotype control or anti-DENV antibody 90 hr after infection (n = 3–4).
Evans blue in tissues was extracted with formamide and quantified spectrophotometrically. The experiment was repeated 72 hr after infection and similar results
were obtained.
(F) Gastrointestinal bleeding in the small intestine 84 hr after infection in the presence of anti-DENV antibodies. Mice were perfused with PBS before pictures were
taken. Tissues from one representative animal per group are shown.
P values from two-tailed unpaired t test with Welch’s correction, c.i. 95%, *p% 0.05, **p% 0.01, ***p% 0.001, error bars represent SEM, n is the number of mice
per group. See also Figure S1.
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ADE of LSEC Infection and Dengue Disease in Mice72 hr (Figure 4A). In all other organs examined, no significant
differences between anti-DENV-treated and isotype-treated
mice were observed until 90 hr after infection, at which time viral
RNA levels were higher in the kidney, stomach, large intestine,
and brain of anti-DENV-treated mice (Figure 4B). At 90 hr post-
infection, infectious virus was detected in all the organs by
plaque assay on BHK cells (Figure S2), and the differences
observed in viral RNA levels were confirmed. In summary, viral
RNA levels were first increased in the liver of anti-DENV-treated
mice by 48 hr, followed by a general increase in other organs,
most notably the small intestine.
Interactions between FcgRs and Virus-Bound
Antibodies Mediate Increased Levels of Virus
In vitro, ADE of DENV infection requires the presence of FcgRs
on target cells (Halstead et al., 1977), suggesting the involvement
of the Fc portion of the antibody. To test this in vivo, mice were
infected with 53 108 GE S221 and, 1 day later, treated with equi-
molar amounts of either an isotype control antibody, the anti-
DENV antibody 2H2, the F(ab0)2 of 2H2, intact 2H2 and an
FcgR-blocking antibody, or the F(ab0)2 of 2H2 chemically
coupled to the isotype control. Viral RNA levels in the liver
were elevated 72 hr after infection only in the mice treated with
either intact anti-DENV antibody or the F(ab0)2 of 2H2 chemically
coupled to the isotype control (Figure 4C). In addition, blocking
FcgRs II and III prevented the increase in viral load in miceCell Hostadministered intact 2H2 (Figure 4C). These results demonstrate
that ADE requires an interaction between the Fc portion of the
virus-bound antibodies and FcgRs. The DENV reactivity and
the presence (or absence) of the Fc portion of the isotype control,
the anti-DENV antibody 2H2, the F(ab0)2 of 2H2, and the F(ab0)2 of
2H2 chemically coupled to the isotype control were confirmed by
ELISA on DENV2-coated plates using a secondary antibody
specific for either the Fc portion (Figure S3, left panel) or the
F(ab0)2 portion (Figure S3, right panel).
Antibodies Enhance Infection of LSECs
The liver and small intestine were the tissues in which levels of
viral RNA were most elevated in anti-DENV-treated mice relative
to isotype-treated mice. To investigate infection of the cells in
those tissues, total mononuclear cells were purified, stained for
various surface molecules and intracellular DENV membrane
protein (DENV prM, using clone 2H2), and analyzed by flow
cytometry. In the liver, DENV prM+ cells were CD45 and
CD31+, which is phenotypically consistent with LSECs (Katz
et al., 2004) (Figure 5). A large percentage of LSECs expressed
DENV prM at 48 and 72 hr in anti-DENV-treated mice, whereas
the percentage of DENV prM+ LSECs was low in isotype-treated
mice (Figure 5, upper and lower left part). Expression of DENV
prM was negligible in CD45+ and CD45CD31 cell populations
in both groups of mice. In the small intestine (Figure 6, upper and
lower left part), the DENV prM+ cells were MHC-II+, CD103,& Microbe 7, 128–139, February 18, 2010 ª2010 Elsevier Inc. 131
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Figure 4. Administration of Anti-DENV Antibodies Results in an FcgR-Dependent Increase in Viral Load in DENV-Infected Mice
(A and B) Viral RNA levels were quantified by qRT-PCR 12, 24, 48, 72, and 90 hr after infection of AG129 mice (53 108 GE S221 i.v. on day 0) in the presence or
absence of DENV-specific antibody (15 mg clone 2H2, administered on days 1 and 1). Symbols represent mean ± SEM, n = 3–6.
(C) DENV-infected AG129 mice (53 108 GE S221 i.v. on day 0) were treated on day 1 with equimolar amounts of intact anti-DENV antibody (15 mg, n = 8), intact
anti-DENV antibody (15 mg) in the presence of FcgR-blocking antibody (500 mg clone 2.4G2 i.v. on day 0 and 1, n = 7), anti-DENV F(ab0)2 fragment (10 mg, n = 4), or
anti-DENV F(ab0)2 fragment chemically coupled 1:1 to an isotype control (25 mg, n = 4). As a control, one group was treated with an isotype control (n = 4).
P values from two-tailed unpaired t test with Welch’s correction, c.i. 95%, *p% 0.05, **p% 0.01, ***p% 0.001, n is the number of mice per group; MLN, mesen-
teric lymph node; PLN, peripheral lymph nodes (axillary, brachial and inguinal); BM,: bone marrow. See also Figures S2 and S3. Error bars represent SEM.
Cell Host & Microbe
ADE of LSEC Infection and Dengue Disease in MiceLy-6C, CD11clo-int, CD11b+, and F4/80+, consistent with the
phenotype of lamina propria macrophages (LPMs) (Uematsu
et al., 2008) (MHC-II+ cell populations in Figure 6 and MHC-II
cell populations in Figure S4). At 48 hr, a small percentage of
LPMs expressed DENV prM in both isotype-treated and anti-
DENV-treated mice. This percentage was similar in both groups,
indicating that infection of LPMs is not directly affected by anti-
DENV antibodies. By 72 hr, the percentage of prM+ LPMs had132 Cell Host & Microbe 7, 128–139, February 18, 2010 ª2010 Elsevincreased in both groups but was three times higher in anti-
DENV-treated mice.
To assess viral replication in situ, frozen tissue sections were
stained for DENV nonstructural protein 3 (NS3), which is absent
from the virion, but produced by the host cell during viral genome
translation. In the liver, NS3 colocalized with cells expressing
CD31, confirming productive infection of LSECs (Figure 5, lower
right part). Colocalization of NS3 with CD68 was observed onlyier Inc.
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Figure 5. Anti-DENV Antibodies Increase Infection of LSECs in DENV-Infected Mice
Percentage of DENV antigen-positive cells in different liver cell populations. Gating is indicated on the left, population statistics are indicated in the bar graph on
the right. Representative dot plots of DENV antigen staining of LSECs (R3 gate) and immunohistochemical staining of liver sections, stained for DENV NS3 (green),
CD31 (red), and CD68 (blue) (low- and high-magnification images are on the left and right, respectively, and the size is indicated by the scale bars). n = 3 per group;
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**p% 0.01, ***p% 0.001. Error bars represent SEM.
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macrophages are located in the liver sinusoids, surrounded by
CD31+ LSECs. In the small intestine, all NS3 localized to cells
expressing F4/80 and CD68 (Figure 6, lower right part), confirm-Cell Hosting productive infection of LPMs. To determine the effect of
anti-DENV antibodies on infection of LSECs by non-mouse-
passaged DENV strains, immunofluorescent staining was
performed on liver sections from anti-DENV-treated and& Microbe 7, 128–139, February 18, 2010 ª2010 Elsevier Inc. 133
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Figure 7. Antibodies Enhance Infection of LSECs by DENV Clinical Isolate Strains of Each Serotype
AG129 mice were infected with following clinical isolates: DENV1 Julia (53 106 FIU), DENV2 PL046 (1.53 107 FIU), DENV3 UNC3001 (2.53 105 FIU), or DENV4
H241 (3.5 3 106 FIU) on day 0, and 50 mg of anti-DENV antibody 2H2 was administered on days 1 and 1. On day 3, liver sections were stained for DENV NS3
(green), CD31 (red), and CD68 (blue). Low- and high-magnification images are on the left and right, respectively, and the size is indicated by the scale bars.
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isolates: DENV1 Julia (Nicaragua), DENV2 PL046 (Taiwan),
DENV3 UNC3001 (Sri Lanka), or DENV4 H241 (Philippines).
Anti-DENV antibodies greatly increased infection of LSECs by
all clinical isolates (Figure 7).
DISCUSSION
Using an in vivo model for ADE-induced severe dengue dis-
ease, we have shown that anti-DENV antibodies enhance infec-
tion of LSECs, ultimately resulting in increased infection of
other tissues, low platelet counts, elevated hematocrit, cytokine
storm, intestinal hemorrhage, and early death, which was pre-
vented by neutralizing TNF. As this model is based on passive
transfer of anti-DENV antibodies, it is analogous to DHF/DSS in
infants, which is believed to result from ADE mediated by
DENV-specific maternal antibodies. With respect to secondary
infections, this work separates the antibody component from
other aspects of a secondary immune response, enabling the
role of antibodies in DENV-induced disease to be studied in
isolation.
Although many of the symptoms of human DHF/DSS were
observed in the anti-DENV-treated mice in our study, the fact
that we used IFN receptor-deficient mice must be taken into
account when interpreting our results because of the potentialFigure 6. An Increased Percentage of LPMs Are Infected Following Ele
Percentage of DENV antigen-positive cells in MHC-II+ lamina propria cell populatio
an isotype control antibody), and population statistics are indicated in the bar gra
and immunohistochemical staining of small intestine sections, stained for DENV
are on the left and right, respectively, and the size is indicated by the scale bars).
are shown; P values from two-tailed unpaired t test with Welch’s correction, c.i. 95
SEM.
Cell Hostrole of IFN in both pathogenesis and protection. This study would
ideally have been performed using immunocompetent mice, but
wild-type mice did not permit detectable viral replication and did
not exhibit signs of disease. A potential explanation for this is that
although DENV is able to inhibit IFN signaling in human cells
(Jones et al., 2005; Munoz-Jordan et al., 2003), viruses that are
able to block IFN signaling in human cells have been shown to
fail to do so in mouse cells (Young et al., 2001). Accordingly, it
seems that the virus used in the present study is unable to suffi-
ciently disrupt IFN signaling to allow replication in wild-type
mice. Thus, although studying DENV infection in complete
absence of IFN signaling has limitations, IFN receptor-deficient
mice permit viral replication and develop disease much like
that observed in humans, making these mice useful for studying
DENV-induced disease. The use of a mouse-passaged virus for
these studies could potentially be another limitation. However,
increased infection of LSECs via ADE was not restricted to the
mouse-passaged dengue strain, as Ab-mediated increased
infection of LSECs was confirmed with all the DENV strains
tested, including clinical isolates from each serotype. Interest-
ingly, overt disease was only observed in mice infected with
the mouse-passaged strain S221, likely due to its increased
ability to replicate in mice relative to the clinical isolates.
The present study shows in vivo that anti-DENV antibodies
specifically enhance infection of LSECs, as only the livervated Infection of LSECs in Mice Treated with Antibodies
ns. Gating is indicated on the top (the gray histogram depicts cells stained with
ph below. Representative dot plots of DENV antigen staining of LPMs (R3 gate)
NS3 (green), CD68 (red), and F4/80 (blue) (low- and high-magnification images
n = 3 per group; representative FACS plots and immunohistochemistry images
%, *p% 0.05, **p% 0.01, ***p% 0.001. See also Figure S4. Error bars represent
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tion. Anti-DENV antibodies seem to directly and exclusively
enhance infection of LSECs, subsequently resulting in the
increased infection observed later in other organs. The finding
that LPMs are infected to the same level at 48 hr regardless of
the presence of antibody provides support for this scenario.
Only after increased replication in LSECs has occurred is a higher
level of infection in LPMs detected in anti-DENV-treated mice.
Similarly, in other organs, higher viral loads in anti-DENV-treated
mice were detected only after increased replication in LSECs.
A role for LSECs in permitting ADE seems reasonable, consid-
ering that LSECs specialize in filtering small particles, including
particles the size of DENV virions, out of the bloodstream (Elve-
vold et al., 2008), promote active antigen uptake via FcgRs (Elve-
vold et al., 2008), and constitutively express L-SIGN (Bashirova
et al., 2001) and mannose receptors (Elvevold et al., 2008), which
have been demonstrated to facilitate DENV infection (Miller et al.,
2008; Tassaneetrithep et al., 2003).
ADE in vitro results from increased attachment of virus to the
surface of cells through interaction of antibody-virus complexes
with cellular FcgRs (Halstead et al., 1977), which subsequently
results in enhanced infection. Cells that lack attachment factors,
and consequently do not permit efficient attachment of virus in
the absence of antibodies, are most susceptible to ADE (Boon-
nak et al., 2008). This likely occurs because, in the absence of
attachment factors, binding of antibody-virus complexes with
cell-surface FcgRs greatly increases virus-cell interactions. On
cells that express high levels of attachment factors, it is likely
that the virus-cell interactions that are antibody independent
substantially exceed those that are antibody dependent and,
therefore, the effect of antibodies becomes negligible. Accord-
ingly, the effect of ADE in vitro is most pronounced on mono-
cytes (Kou et al., 2008) and macrophages (Blackley et al.,
2007), which exhibit very low susceptibility to antibody-indepen-
dent infection in vitro (Diamond et al., 2000), and on DCs
expressing low levels of attachment factors (Boonnak et al.,
2008).
In contrast to the findings that, in vitro, macrophages and
monocytes are not easily infected in the absence of antibodies,
we have found that, in mice, macrophages of the small intestine
lamina propria (as described above), as well as macrophages
and DCs of many other tissues throughout the mouse (data
not shown), are highly susceptible to antibody-independent
infection but not subject to ADE. LSECs were the only cells sup-
porting ADE in vivo, and they were, at the viral dose used in this
study, only infected to a limited extent in the absence of anti-
body. It is unclear whether the discrepancy between our results
and those obtained with isolated human cells is due to differ-
ences between mice and humans or due to differences in
experiments performed in vitro versus in vivo. Regardless, our
finding that, in mice, ADE occurs with LSECs, but not other
cell populations, is in line with the observation that ADE occurs
with cells that permit only low levels of antibody-independent
infection.
An important point to consider is the influence of potential
differences between mouse and human LSECs on our results.
Attachment factors on human and mouse LSECs may differ in
their expression level and ability to bind DENV, and therefore
mouse and human LSECs may differ in their susceptibility to136 Cell Host & Microbe 7, 128–139, February 18, 2010 ª2010 ElsevADE. It could be argued that ADE is readily observed on mouse
LSECs because they potentially lack attachment factors analo-
gous to the ones binding DENV on human LSECs and, therefore,
mouse LSECs could permit ADE even if human LSECs do not.
We believe that this is not the case, because mouse LSECs,
while infected only to low levels in the absence of antibodies at
the dose used in the present study, permit much greater levels
of antibody-independent infection at higher viral doses (data
not shown). This suggests that mouse LSECs, like human
LSECs, do express dengue attachment factors but, unlike
macrophages, not at levels high enough to override the effect
of antibodies.
The liver has been suggested to be an important site of repli-
cation for DENV in humans (Rosen et al., 1999), and the presence
of DENV RNA or antigen in the liver of patients who succumbed
to DHF/DSS has been reported (Balsitis et al., 2009; Jessie et al.,
2004; Rosen et al., 1999). However, results from studies investi-
gating the cellular localization of DENV antigen within the liver
have been inconsistent. While Jessie et al. reported the presence
of antigen in Kupffer and endothelial cells, Balsitis and col-
leagues found infection only in hepatocytes. Both experimental
and methodological factors could account for differences in
these findings. Studies have varied based on which viral proteins
were detected, either structural or nonstructural, and whether
polyclonal or monoclonal Abs were used. In our study, cellular
tropism in the liver was assessed using two complementary
methods: flow cytometry using a mAb against prM, and immuno-
histochemistry using polyclonal antibodies against NS3. In con-
trast to previous studies, the cell type permitting DENV infection
was determined by both methods to be LSECs based on the
expression of cellular markers rather than morphology. Addition-
ally, increased infection of LSECs due to antibodies was
observed with four clinical isolates (one of each serotype), further
strengthening our results.
Our results confirm in vivo that even neutralizing antibodies
have the potential to induce ADE (Mehlhop et al., 2007; Pierson
et al., 2007), provided that the occupancy threshold required for
neutralization is not reached (Burton, 2002). To be neutralizing,
and therefore optimally protective, an antibody must be of high
enough affinity for neutralizing epitopes on the surface of the
virus, and it must be present in sufficient concentration (Pierson
and Diamond, 2008). Failure to fulfill either of these requirements
will prevent neutralization. This idea can be applied to sequential
DENV infections to explain why antibodies induced by one DENV
serotype, although protective against that serotype (Whitehead
et al., 2007), may increase the risk of severe disease upon infec-
tion with a heterologous serotype due to enhanced infection of
cells bearing FcgRs by subneutralized viral particles (Halstead,
2003). It seems likely that due to differences in the surface anti-
gens between serotypes, only some of the antibodies raised
against one will react with another, and, of the cross-reactive
antibodies, some may have a reduced affinity for the second
serotype. Therefore, during a secondary infection by a heterolo-
gous serotype, the threshold for neutralization is less likely to be
reached and, consequently, ADE-mediated severe disease is
more likely to occur. In our study, this is exemplified by the
fact that the cross-reactive, neutralizing mAb 4G2 increased
mean survival time at high doses but reduced mean survival
time at low doses, demonstrating in vivo that neutralization andier Inc.
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binding to the surface of viral particles.
Multiple factors have been hypothesized to influence the
severity of dengue disease, including subneutralizing levels of
antibodies (Halstead, 1982), virus serotype and genotype (Rico-
Hesse, 2007), and activation of serotype cross-reactive memory
T cells (Rothman, 2003). Here we demonstrate that the presence
of subneutralizing levels of DENV-specific antibodies can be
sufficient to modify the course of infection, resulting in higher viral
load, and ultimately severe disease characterized by increased
cytokine release, increased vascular permeability, low platelet
counts, elevated hematocrit, gastrointestinal hemorrhage, and
early death. Beyond dengue disease, our findings have implica-
tions for the fields of humoral immunity and vaccine design, as
they suggest a mechanism by which subprotective humoral
responses may, under some circumstances, have pathological
consequences.EXPERIMENTAL PROCEDURES
Mice
Sv/129 mice deficient in type I (A129) or type I and II (AG129) IFN receptors,
obtained from H. Virgin, and all other mice (purchased from The Jackson Labo-
ratory) were housed under SPF conditions. All animal experiments were
approved by the Animal Care Committee at La Jolla Institute for Allergy and
Immunology (LIAI).Antibodies
2H2 (IgG2a anti-DENV1-4 prM), 4G2 (IgG2a anti-all flavivirus E), 3H5 (IgG1
anti-DENV2 E), 15F3 (IgG1 anti-DENV1 NS1), and C44 (IgG2a anti-colchicine)
hybridomas were purchased from ATCC. Hybridomas were grown in PFHM-II
(GIBCO) with penicillin (100 U/ml), streptomycin (100 mg/ml), and 55 mM b-mer-
captoethanol. Clarified supernatants were concentrated using Amicon 50,000
MWCO filter units (Millipore) and purified using protein G-coupled resin
according to the manufacturer’s instructions (Pierce). F(ab0)2 fragments were
prepared using the F(ab0)2 Preparation Kit for mouse IgG2a (Pierce) by digest-
ing purified IgG with immobilized pepsin at 37C for 4 hr. The digest was
incubated with protein A-coupled resin to remove large Fc fragments and undi-
gested antibody. Unbound protein was dialyzed in 20,000 MWCO Slide-A-
Lyzer cassettes (Pierce) to remove any remaining digested fragments. To
couple 2H2 F(ab0)2 fragments to the isotype control antibodies, F(ab0)2 frag-
ments were labeled with Sulfo-SMCC (Pierce) and mixed at an equimolar ratio
with isotype control antibodies pretreated with SATA (Pierce). All antibodies
were dialyzed against PBS, concentrated, and sterile filtered prior to use in
experiments. The purity of antibody preparations was verified by SDS-
PAGE, and binding to DENV was assessed by ELISA. Protein content was
quantified using a BCA protein assay kit (Pierce).Viruses
As previously described (Shresta et al., 2006), to generate D2S10, the C6/36
mosquito cell-adapted DENV2 isolate PL046, obtained from Dr. Huan-Yao
Lei (National Cheng Kung University, Taiwan), was passaged ten times
between the serum of AG129 mice and C6/36 mosquito cells. The biological
clone S221 was obtained from D2S10 by growing virus from individual plaques
on BHK monolayers three times serially. DENV1 strain Julia (Nicaraguan
isolate) was obtained from Dr. Eva Harris, UC Berkeley. DENV3 strain
UNC3001 (isolate from Sri Lanka) was obtained from Dr. Aravinda de Silva,
UNC Chapel Hill. DENV4 strain H241 (isolate from the Philippines) was
purchased from ATCC. Julia, PL046, UNC3001, and H241 were quantified
using flow cytometry as described previously (Lambeth et al., 2005) and ex-
pressed as FIUs. Viral stocks were prepared as previously described (Pre-
stwood et al., 2008). For ELISA, virus was purified over a sucrose gradient
as previously described (Prestwood et al., 2008).Cell HostImmune Serum
Immune serum was obtained from AG129 mice infected with 1.5 3 106 FIUs
(as defined by infection of C6/36 cells) of DENV1 strain Julia, DENV2 strain
E128-IC (Prestwood et al., 2008) (used due to its reduced capacity to cause
paralysis in AG129 mice compared to the parental strain PL046), DENV3 strain
UNC3001, DENV4 strain H241.
Administration of Virus and Antibody
If not stated otherwise, AG129 mice were inoculated i.v. with 5 3 108 GE of
S221. Antibody or serum was administered intraperitoneally in 200 ml PBS
1 day before and 1 day after infection.
Viral RNA Quantification
As described previously (Prestwood et al., 2008), tissues were collected into
RNAlater (QIAGEN) and subsequently homogenized. RNA was isolated and
DENV and relative 18S were quantified using real-time qRT-PCR.
DENV ELISA
Sucrose gradient-purified S221 (109 GE per well) was used to coat 96-well
plates. Next, virus on plates was UV inactivated, and plates were washed of
unbound virus using 0.05% (v/v) Tween 20 (Sigma) in PBS (GIBCO). After
blocking with 2% (w/v) BSA in PBS (1 hr, room temperature), purified mono-
clonal antibodies or F(ab0)2 fragments were titrated on virus and unbound anti-
body was removed by washing. Bound antibody was detected using HRP-
conjugated goat anti-mouse IgG antibodies specific for either Fc or F(ab0)2
portions (Jackson Immunoresearch) and TMB (eBioscience).
Biological Activity of Sera
Three-fold serial dilutions of serum were incubated with 1.5 3 1010 GE of
S221 for 1 hr at room temperature in a total volume of 250 ml PBS. Subse-
quently, 2 3 106 C6/36 cells were infected with 200 ml of the virus-antibody
mix for 1 hr at 28C. Cells were washed two times with 1 ml of PBS, and
the cells were incubated at 28C in 500 ml L-15 medium (GIBCO) containing
5% FCS, penicillin (100 U/ml) and streptomycin (100 mg/ml) for 23 hr. For
each antibody dilution, the percent of infected cells was determined by flow
cytometry as previously described (Lambeth et al., 2005) using 2H2-biotin
and streptavidin-APC (Biolegend). The percent of infected cells was normal-
ized to 100% (infection without antibody), and the average of two experiments
is shown.
Measurement of Cytokines
Serum samples were analyzed by the Immune Reconstitution Facility, Duke
University, Durham, NC, USA, using the Bio-Plex Multiplex Cytokine Assay
(Bio-Rad). TNF in serum was measured using the Ready-SET-Go! TNF ELISA
kit (eBioscience).
Hematologic Analysis
Platelet counts and hematocrit were measured on a Hemavet 950FS (Drew)
according to the manufacturer’s instructions.
Neutralization of TNF, IL-6, and Blocking of IL-10 Receptor
and FcgRs II and III
Functional grade rat anti-TNF (clone MP6-XT22; eBioscience) was used to
neutralize TNF as previously described (Shresta et al., 2006), except that
100 mg was injected i.p. each day for 4 days following infection, starting on
day 1. As previously described, 500 mg of functional grade rat anti-IL-6
(Starnes et al., 1990) (clone MP5-20F3; BioXCell) or anti-IL10R (Brooks
et al., 2006) (clone 1B1.3A; BioXCell) was administered i.p. on day 2 and 3.
To block FcgRs II and III, 500 mg of mAb 2.4G2 (BioXCell) was administered
i.v. on days 0 and 2.
Vascular Leakage Assay
Evans blue (Sigma), which binds avidly to albumin, is used to assess vascular
permeability, as the extravasation of albumin into tissues indicates relative
integrity of the vascular endothelium. Evans blue (0.2 ml, 0.5% [w/v] in PBS)
was administered i.v. and, after 15 min, animals were sacrificed and exten-
sively perfused with PBS. Livers were collected into formamide and, after& Microbe 7, 128–139, February 18, 2010 ª2010 Elsevier Inc. 137
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at 610 nm.
Flow Cytometry
Tissues were collected into RPMI (GIBCO) containing 10% fetal calf serum
(Gemini Bio-Products) and stored on ice. To isolate cells from the small intes-
tine lamina propria, Peyer’s patches were excised and the tissue was filleted
longitudinally and washed in cold PBS. Epithelial cells were removed from
segmented tissue by agitation for 30 min at 37C in PBS containing 10%
(v/v) FCS, EDTA (10 mM), HEPES (20 mM), penicillin (100 U/ml), streptomycin
(100 mg/ml), and polymyxin B (10 mg/ml; Calbiochem), followed by extensive
washing with PBS. The small intestine and liver were minced and digested
for 20 min at 37C with agitation in RPMI containing 10% fetal calf serum
and 1.5 mg/ml collagenase VIII (Sigma) in approximately 25 ml. Tissues were
immediately washed in RPMI and digests were collected via centrifugation.
Resuspended tissues were pressed through 70 mm strainers (BD) using the
plunger of 3 ml syringes (BD). Liberated cells were collected and pelleted
by centrifugation. Cells were resuspended in a 14.7% Optiprep (Sigma) solu-
tion diluted in 150 mM NaCl with 10 mM HEPES (pH 7.4) and layered over
22.2% Optiprep solution diluted in the same buffer. Cells were spun for
20 min at 750 3 g at 25C and washed immediately after with RPMI. 2 3 105
cells per well were plated in 96-well plates, and FcgRs were blocked with
1 mg of mAb 2.4G2. Cells from the small intestine were stained using FITC
anti-Ly-6C (PharMingen), PE anti-CD103 (PharMingen), PE-Cy7 anti-CD11c
(PharMingen), APC anti-CD11b (Biolegend), Pacific Blue anti-MHC II (Biole-
gend), Alexa-Fluor 700 anti-Gr-1 (PharMingen), and PerCP-Cy5.5 anti-F4/80
(Biolegend) or with appropriately labeled isotype controls. Cells from the liver
were stained with PE anti-CD31 (PharMingen) and PE-Cy7 anti-CD45 (Phar-
Mingen). Cells were fixed and permeabilized using the Cytofix/Cytoperm Kit
(BD). For intracellular staining, all steps were performed in 13 BD Perm/
Wash. Cells were blocked briefly and stained for 30 min with biotinylated
2H2 or isotype control. After washing, cells were stained with streptavidin
conjugated to either APC (eBioscience) for the liver cells or APC-Alexa Fluor
750 (Caltag Laboratories) for the small intestine cells. The gate for DENV
antigen-positive cells was set at 0.1% of the isotype control staining. Data
were collected using an LSR II (BD) and analyzed with FlowJo software
(Tree Star).
Immunohistochemistry
Tissues were embedded in O.C.T. compound (Sakura). Sections (6 mm) were
cut and stored at 80C. Frozen sections were thawed and fixed for 10 min
in acetone at 25C, followed by 8 min in 1% paraformaldehyde (EMS) in
100 mM dibasic sodium phosphate containing 60 mM lysine and 7 mM sodium
periodate at pH 7.4 on ice. Sections were blocked first using the Avidin/Biotin
Blocking Kit (Vector Labs) followed by 5% normal goat serum (Caltag Labora-
tories) and 1% BSA (Sigma) in PBS. Sections were stained overnight with puri-
fied rabbit polyclonal anti-DENV NS3 (a generous gift from the Novartis Insti-
tute for Tropical Diseases, Singapore) and either rat anti-mouse CD31
(PharMingen) for liver sections or PE-labeled rat anti-mouse F4/80 (Caltag
Laboratories) for small intestine sections. Sections were then washed and
stained with DyLight 649-labeled goat anti-rabbit IgG (Jackson Immunore-
search) and biotinylated goat anti-rat IgG (PharMingen) and then with PE-
labeled streptavidin (eBioscience). Sections were then blocked again with
Avidin/Biotin Blocking Kit followed by 10% rat serum in PBS and finally stained
with biotin anti-mouse CD68 (Serotec) and FITC-labeled streptavidin (Phar-
Mingen). Images were recorded using a Marianas deconvolution fluorescence
microscope (3i) and prepared using Adobe Photoshop.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.chom.2010.01.004.
ACKNOWLEDGMENTS
The project described was supported by National Institutes of Health (NIH)
grants AI060989 and AI077099-01 to S.S., NIH grant U54 AI057157 from
Southeast Regional Center of Excellence for Emerging Infections and Biode-138 Cell Host & Microbe 7, 128–139, February 18, 2010 ª2010 Elsevfense to P.F. Sparling, a fellowship from the Swiss National Science Founda-
tion to R.M.Z. (PBEZB-118877), and a fellowship from the Novartis Foundation
to R.M.Z. We thank Drs. Chris Benedict, Carl Ware, Shane Crotty, Lauren
Yauch, and Stuart Perry at La Jolla Institute for Allergy and Immunology
(LIAI) for critical reading of the manuscript. We thank Robyn Miller, Dr. Olga
Turovskaya, Sarala Joshi, Dr. Satoshi Fukuyama, Steven Lada, and Burton
Barnett for technical help.
Received: November 14, 2009
Revised: December 29, 2009
Accepted: January 12, 2010
Published online: February 11, 2010
REFERENCES
Balsitis, S.J., Coloma, J., Castro, G., Alava, A., Flores, D., McKerrow, J.H.,
Beatty, P.R., and Harris, E. (2009). Tropism of dengue virus in mice and
humans defined by viral nonstructural protein 3-specific immunostaining.
Am. J. Trop. Med. Hyg. 80, 416–424.
Bashirova, A.A., Geijtenbeek, T.B., van Duijnhoven, G.C., van Vliet, S.J., Eiler-
ing, J.B., Martin, M.P., Wu, L., Martin, T.D., Viebig, N., Knolle, P.A., et al. (2001).
A dendritic cell-specific intercellular adhesion molecule 3-grabbing noninte-
grin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal
endothelial cells and promotes HIV-1 infection. J. Exp. Med. 193, 671–678.
Blackley, S., Kou, Z., Chen, H., Quinn, M., Rose, R.C., Schlesinger, J.J., Cop-
page, M., and Jin, X. (2007). Primary human splenic macrophages, but not T or
B cells, are the principal target cells for dengue virus infection in vitro. J. Virol.
81, 13325–13334.
Boonnak, K., Slike, B.M., Burgess, T.H., Mason, R.M., Wu, S.J., Sun, P.,
Porter, K., Rudiman, I.F., Yuwono, D., Puthavathana, P., et al. (2008). Role of
dendritic cells in antibody-dependent enhancement of dengue virus infection.
J. Virol. 82, 3939–3951.
Brooks, D.G., Trifilo, M.J., Edelmann, K.H., Teyton, L., McGavern, D.B., and
Oldstone, M.B. (2006). Interleukin-10 determines viral clearance or persis-
tence in vivo. Nat. Med. 12, 1301–1309.
Burton, D.R. (2002). Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2,
706–713.
Chaturvedi, U.C., Agarwal, R., Elbishbishi, E.A., and Mustafa, A.S. (2000).
Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis.
FEMS Immunol. Med. Microbiol. 28, 183–188.
Chiu, Y.C., Wu, K.L., Kuo, C.H., Hu, T.H., Chou, Y.P., Chuah, S.K., Kuo, C.M.,
Kee, K.M., Changchien, C.S., Liu, J.W., et al. (2005). Endoscopic findings and
management of dengue patients with upper gastrointestinal bleeding. Am. J.
Trop. Med. Hyg. 73, 441–444.
Diamond, M.S., Edgil, D., Roberts, T.G., Lu, B., and Harris, E. (2000). Infection
of human cells by dengue virus is modulated by different cell types and viral
strains. J. Virol. 74, 7814–7823.
Elvevold, K., Smedsrod, B., and Martinez, I. (2008). The liver sinusoidal endo-
thelial cell: a cell type of controversial and confusing identity. Am. J. Physiol.
294, G391–G400.
Goncalvez, A.P., Engle, R.E., St Claire, M., Purcell, R.H., and Lai, C.J. (2007).
Monoclonal antibody-mediated enhancement of dengue virus infection in vitro
and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. USA 104,
9422–9427.
Green, S., Vaughn, D.W., Kalayanarooj, S., Nimmannitya, S., Suntayakorn, S.,
Nisalak, A., Lew, R., Innis, B.L., Kurane, I., Rothman, A.L., et al. (1999). Early
immune activation in acute dengue illness is related to development of plasma
leakage and disease severity. J. Infect. Dis. 179, 755–762.
Halstead, S.B. (1979). In vivo enhancement of dengue virus infection in rhesus
monkeys by passively transferred antibody. J. Infect. Dis. 140, 527–533.
Halstead, S.B. (1982). Immune enhancement of viral infection. Prog. Allergy
31, 301–364.
Halstead, S.B. (2003). Neutralization and antibody-dependent enhancement
of dengue viruses. Adv. Virus Res. 60, 421–467.
Halstead, S.B. (2007). Dengue. Lancet 370, 1644–1652.ier Inc.
Cell Host & Microbe
ADE of LSEC Infection and Dengue Disease in MiceHalstead, S.B., Nimmannitya, S., Yamarat, C., and Russell, P.K. (1967).
Hemorrhagic fever in Thailand; recent knowledge regarding etiology. Jpn.
J. Med. Sci. Biol. 20 (Suppl ), 96–103.
Halstead, S.B., O’Rourke, E.J., and Allison, A.C. (1977). Dengue viruses and
mononuclear phagocytes. II. Identity of blood and tissue leukocytes support-
ing in vitro infection. J. Exp. Med. 146, 218–229.
Jessie, K., Fong, M.Y., Devi, S., Lam, S.K., and Wong, K.T. (2004). Localization
of dengue virus in naturally infected human tissues, by immunohistochemistry
and in situ hybridization. J. Infect. Dis. 189, 1411–1418.
Jones, M., Davidson, A., Hibbert, L., Gruenwald, P., Schlaak, J., Ball, S.,
Foster, G.R., and Jacobs, M. (2005). Dengue virus inhibits alpha interferon
signaling by reducing STAT2 expression. J. Virol. 79, 5414–5420.
Katz, S.C., Pillarisetty, V.G., Bleier, J.I., Shah, A.B., and DeMatteo, R.P. (2004).
Liver sinusoidal endothelial cells are insufficient to activate T cells. J. Immunol.
173, 230–235.
Kittigul, L., Pitakarnjanakul, P., Sujirarat, D., and Siripanichgon, K. (2007). The
differences of clinical manifestations and laboratory findings in children and
adults with dengue virus infection. J. Clin. Virol. 39, 76–81.
Kou, Z., Quinn, M., Chen, H., Rodrigo, W.W., Rose, R.C., Schlesinger, J.J., and
Jin, X. (2008). Monocytes, but not T or B cells, are the principal target cells for
dengue virus (DV) infection among human peripheral blood mononuclear cells.
J. Med. Virol. 80, 134–146.
Lambeth, C.R., White, L.J., Johnston, R.E., and de Silva, A.M. (2005). Flow
cytometry-based assay for titrating dengue virus. J. Clin. Microbiol. 43,
3267–3272.
Mehlhop, E., Ansarah-Sobrinho, C., Johnson, S., Engle, M., Fremont, D.H.,
Pierson, T.C., and Diamond, M.S. (2007). Complement protein C1q inhibits
antibody-dependent enhancement of flavivirus infection in an IgG subclass-
specific manner. Cell Host Microbe 2, 417–426.
Miller, J.L., deWet, B.J., Martinez-Pomares, L., Radcliffe, C.M., Dwek, R.A.,
Rudd, P.M., and Gordon, S. (2008). The mannose receptor mediates dengue
virus infection of macrophages. PLoS Pathog. 4, e17. 10.1371/journal.ppat.
0040017.
Munoz-Jordan, J.L., Sanchez-Burgos, G.G., Laurent-Rolle, M., and Garcia-
Sastre, A. (2003). Inhibition of interferon signaling by dengue virus. Proc.
Natl. Acad. Sci. USA 100, 14333–14338.
Pierson, T.C., and Diamond, M.S. (2008). Molecular mechanisms of antibody-
mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10, e12.Cell HostPierson, T.C., Xu, Q., Nelson, S., Oliphant, T., Nybakken, G.E., Fremont, D.H.,
and Diamond, M.S. (2007). The stoichiometry of antibody-mediated neutrali-
zation and enhancement of West Nile virus infection. Cell Host Microbe 1,
135–145.
Prestwood, T.R., Prigozhin, D.M., Sharar, K.L., Zellweger, R.M., and Shresta,
S. (2008). A mouse-passaged dengue virus strain with reduced affinity for hep-
aran sulfate causes severe disease in mice by establishing increased systemic
viral loads. J. Virol. 82, 8411–8421.
Rico-Hesse, R. (2007). Dengue virus evolution and virulence models. Clin.
Infect. Dis. 44, 1462–1466.
Rosen, L., Drouet, M.T., and Deubel, V. (1999). Detection of dengue virus RNA
by reverse transcription-polymerase chain reaction in the liver and lymphoid
organs but not in the brain in fatal human infection. Am. J. Trop. Med. Hyg.
61, 720–724.
Rothman, A.L. (2003). Immunology and immunopathogenesis of dengue
disease. Adv. Virus Res. 60, 397–419.
Shresta, S., Sharar, K.L., Prigozhin, D.M., Beatty, P.R., and Harris, E. (2006).
Murine model for dengue virus-induced lethal disease with increased vascular
permeability. J. Virol. 80, 10208–10217.
Starnes, H.F., Jr., Pearce, M.K., Tewari, A., Yim, J.H., Zou, J.C., and Abrams,
J.S. (1990). Anti-IL-6 monoclonal antibodies protect against lethal Escherichia
coli infection and lethal tumor necrosis factor-alpha challenge in mice.
J. Immunol. 145, 4185–4191.
Tassaneetrithep, B., Burgess, T.H., Granelli-Piperno, A., Trumpfheller, C.,
Finke, J., Sun, W., Eller, M.A., Pattanapanyasat, K., Sarasombath, S., Birx,
D.L., et al. (2003). DC-SIGN (CD209) mediates dengue virus infection of human
dendritic cells. J. Exp. Med. 197, 823–829.
Uematsu, S., Fujimoto, K., Jang, M.H., Yang, B.G., Jung, Y.J., Nishiyama, M.,
Sato, S., Tsujimura, T., Yamamoto, M., Yokota, Y., et al. (2008). Regulation of
humoral and cellular gut immunity by lamina propria dendritic cells expressing
Toll-like receptor 5. Nat. Immunol. 9, 769–776.
Whitehead, S.S., Blaney, J.E., Durbin, A.P., and Murphy, B.R. (2007). Pros-
pects for a dengue virus vaccine. Nat. Rev. 5, 518–528.
Young, D.F., Chatziandreou, N., He, B., Goodbourn, S., Lamb, R.A., and Ran-
dall, R.E. (2001). Single amino acid substitution in the V protein of simian virus 5
differentiates its ability to block interferon signaling in human and murine cells.
J. Virol. 75, 3363–3370.& Microbe 7, 128–139, February 18, 2010 ª2010 Elsevier Inc. 139
